Enterome has two unique platforms that are generating highly promising drug candidates:
- Enterome has two unique platforms that are generating highly promising drug candidates:
OncoMimics: highly effective, off-the-shelf immunotherapies against cancers (EO2401, EO2463).
- EndoMimics: a new generation of biologics for inflammatory diseases (EM101), Type 2 diabetes and inflammatory bowel disease.
- EB8018 has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.
- Enterome is headquartered in Paris (France) with operations in Boston (US) and is backed byleading venture capital investors.